X Prize Opens Centenarian Genome Competition

The first scientific team to sequence the genomes of 100 one-hundred year olds wins $10 million. It’s the latest offering from the science competition organization, X Prize Foundation, a non-profit designed to spur science and technology by awarding big cash prizes for significant breakthroughs.

Their most famous and first prize was the Ansari X Prize which started the commercial race to space.

Now the foundation is challenging biologists to sequence the genetic code of 100 centenarians in an effort to learn something new about longevity. Is there a longevity gene or are these folks just doing the right combination of eating right and exercising to get the most out of their lives?

Studies of very healthy elderly people show that they don’t eat a vegetarian diet. They are often obese, smoke and drink and get little exercise. Those who study the healthy elderly find there is something inexplicable that prevents them from getting diseases like Alzheimer’s and they just don’t age like other people.

With more people living longer, the new X Prize genomics competition will shed some light on aging and to see if the secret to a long life is written in our DNA.

Dr. Thomas Perls, an Alzheimer’s researcher at Boston University is the director of the New England Centenarian Study, the largest study of centenarians in the world. He is thrilled that Archon Genomic X Prize is focusing on sequencing the genomes of 100 centenarians.

And he is helping the competition find the one-hundred-plus year olds, drawing from his own study which has a minimum age requirement of 105 to participate.

He says, “It’s very hard to get there without some genetic advantages.”

Noted biologist Craig Venter is co-chairing the Archon Genomics X Prize, which will be judged on accuracy, completeness and the speed and cost of sequencing.

He says, “We need 10,000 genomes, not 100, to start to understand the link between genetics, disease and wellness.” This X Prize is merely the first step in revealing the genetic secrets of a long life.

Irving Kahn will be 106 in December and he says it would be foolish to retire. The investment banker still goes to the office everyday where he enjoys working along side his son and grandson. He reads two financial newspapers every day. He began his career as an investment advisor just before the stock market crashed in 1929.

In 1978, he began his own firm, which now manages more than $700 million in assets. He adapts to the changing times and now communicates with friends and clients all over the world via the Internet. BBC News interviewed him about the 2008 financial crisis in 2008.

If you know people like Irving, send them to the Medco 100 over 100. That’s the search to find the 100 centenarians to have their genomes sequenced.

These people could hold the secrets to better health for us all, hidden within our own genetic code. This prize could also unleash the era of personalized medicine where health and disease treatment will vary based on a person’s DNA.

After the healthy centenarians have been selected the teams will race for the $10 million prize, which will be given to the first team that accurately sequences the whole genome of 100 subjects within 30 days for $1,000 or less per genome, at an error rate no greater than one per million base pairs (that’s 98% accuracy).

The human genome contains more than six billion pairs of nucleotides, the building blocks of DNA. Ultimately, the competition looks to usher in a new era of personalized medicine through sequencing the whole human genome to a level of fidelity never before measured.

Kahn, the oldest living money manager says, “I’m at the stage in life where I get a lot of pleasure out of finding a cheap stock.”

With the new twist on the genomics X Prize, science will begin taking stock of healthy elderly people and study their secret to a long and healthy life.

History of the Archon Genomics X Prize
The $10 million Archon Genomics X PRIZE presented by Medco was originally launched in
October 2006, its purse underwritten by a generous donation from Dr. Stewart and Marilyn
Blusson, challenging scientists and engineers to sequence 100 whole human genomes in 10
days or less for less than $10,000 per genome at an unprecedented rate of accuracy.
In the following years, sequencing technology progressed through multiple platforms, carving
out niche research markets, each with its strengths and weaknesses. Teams originally registered
to compete were not yet able to meet the requirements.

In 2010, Grant Campany, who has 20 years of experience in the life sciences industry, signed on
as Senior Director for the Archon Genomics X PRIZE. A new approach to the competition was
developed by Mr. Campany, X PRIZE Foundation leadership and the competition’s Scientific
Advisory Board, including Dr. Venter, X PRIZE Foundation Scientific Advisory Co-Chair, and
one of the first to sequence the human genome in 2000 and create the first cell with a synthetic
genome in 2010. Recognizing that no single technology was serving medical/clinical
requirements, the Archon Genomics X PRIZE presented by Medco was revitalized to be more
inclusive, relevant and robust.